2017

2016

 
 
 
 
 

2015

 
 
 
 
 
 
 

2014

 
 
 
 

2013

 
 
 
 
 
 

2012

Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by Curcumin: results of a randomised, double-blind, placebo-controlled trial.

Br J Nutr. 2012; 108 (7):1272-9.
Sulfur Mustard [Bis (2-chloroethyl) sulphide] or SM has been used as chemical warfare agent for almost 100 years. SM is a compound with potent alkylating, vesicant, blister-forming, cytotoxic, mutagenic and carcinogenic properties... 

Continue Reading

 
 
 
 
 
 
 

2011

Curcumin and EGCG Suppress Apurinic/Apyrimidinic Endonuclease 1 and Induce Complete Remission in B-cell Non-Hodgkin's lymphoma Patientsl.

Funct Food Health Dis. 2011; 1(12):525-44.

To examine the role of human APE1 in resistance and prognosis in FL patients and to evaluate safety and efficacy of combination of curcumin and epigallocatechin gallate (EGCG) therapy in non-Hodgkin follicular lymphoma patients and their peripheral blood mononuclear cells...

Continue Reading

 
 

2010

Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress.

J Oral Sci. 2010;52(2):251–6.
To test the effect of curcumin in patients with leukoplakia, oral submucous fibrosis and lichen planus by measuring serum and salivary levels of MDA, 8-OHdG and Vitamin C, E before and after curcuminoids administration...

Continue Reading

 
 

2009

The Potential role of Curcumin in Patients with Monoclonal Gammopathy of Undefined Significance- its Effect on Paraproteinemia and the urinary N-Telopeptide of type I collagen bone turnover marker.

Clin Cancer Res. 2009; 15(18):5917-22.
To determine the effect of Curcumin on plasma cells and osteoclasts in patients with MGUS...  

Continue Reading

2008

Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

Clin Cancer Res. 2008; 14(14):4491-9.
To conduct a Phase II study, to determine the biological activity of oral Curcumin in patients with pancreatic cancer... 

Continue Reading

 

2007

Curcumin downregulates NF-κB and related genes in patients with multiple myeloma: results of a Phase I/II study.

Blood 2007 110:Abstract1177.
To evaluate the clinical safety and biologic effects of Curcumin in multiple myeloma (MM) patients who had asymptomatic, relapsed/refractory, or plateau phase disease...  

Continue Reading

 

2006

Combination Treatment With Curcumin and Quercetin of Adenomas in Familial Adenomatous Polyposis.

Clin Gastroenterol Hepatol. 2006; 4:1035–38.
To evaluate the efficacy and toxicity of Curcumin-Quercetin combination to regress intestinal adenomas in subjects suffering from FAP...

Continue Reading

 

Dose escalation of a Curcuminoid formulation.

BMC Complement Altern Med. 2006; 6:10.
To perform a dose escalation study for determining the maximum tolerated dose, safetyprofile, and resultant serum concentration of a single dose of standardized powdered extract (Curcumin C3 Complex ®) obtained from Alleppey finger turmeric... 

Continue Reading

2005

2004

Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance.

Clin Cancer Res. 2004; 10(20):6847-54.
To analyze toxicity of high doses of Curcumin administered orally to patients with advanced cancer. To investigate the systemic effects of Curcumin consumption...

Continue Reading

 
 

1998

Influence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human Volunteers.

Planta Med. 1998; 64(4):353-6.
Curcuminoids, despite showing excellent activity in inhibiting the expression of inflammatory cytokines and inhibition of free radicals, due to its low bioavailability and rapid transformation...

Continue Reading

사빈사 소개

Sabinsa Corporation은 영양, 화장품, 제약 및 식품 산업을 위한 허브 추출물, 기능성화장품원료, 미네랄, 식이 보충제 및 특수 정제 화학물질의 제조, 공급 및 마케팅을 하는 업체입니다.

Read More..

한국 지사

사빈사코리아 주식회사

서울특별시 강남구 테헤란로 151

1610호(역삼동, 역삼하이츠빌딩)

Tel: 02)565-7241

Fax: 02)565-7242

Info.korea@sabinsa.com

 

연락